Placebo-matching Atogepant

DRUG2 trials

Sponsors

Allergan, AbbVie

Conditions

Episodic MigraineMigraine, With or Without Aura

Phase 2

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

CompletedNCT02848326

AllerganMigraine, With or Without Aura

Start: 2016-09-06End: 2018-04-23Updated: 2018-12-06

Phase 3

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

RecruitingNCT05711394

AbbVieEpisodic Migraine

Start: 2023-05-01End: 2028-05-01Target: 450Updated: 2026-09-16

Related Papers

Pharmacokinetics of Atogepant in Healthy Lactating Female Participants: Results from a Phase 1 Lactation Study.

2025-06-021 citations

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.

2025-02-011 citations

Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis

Cephalalgia2024-12-014 citations

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.

2024-03-113 citations

Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)

Neurology2023-04-25

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.

2020-09-01150 citations